Try a new search

Format these results:

Searched for:

person:speyej01

in-biosketch:true

Total Results:

151


Minimal Acute Toxicity Associated With Concurrent Adjuvant Carboplatin and Accelerated Radiation Therapy for Triple Negative Breast Cancer [Meeting Abstract]

Vatner, R.; Fenton-Kerimian, M.; Novik, Y.; Volm, M.; Tiersten, A.; Oratz, R.; Speyer, J.; Formenti, S. C.
ISI:000310542900629
ISSN: 0360-3016
CID: 204692

Efficacy of RAD001/carboplatin in triple-negative metastatic breast cancer: A phase II study [Meeting Abstract]

Singh, Jasmeet Chadha; Volm, Matthew; Novik, Yelena; Speyer, James L; Adams, Sylvia; Omene, Coral Oghenerukevwe; Meyers, Marleen Iva; Smith, Julia Anne; Schneider, Robert; Formenti, Silvia; Goldberg, Judith D; Li, Xiaochun; Davis, Samantha; Beardslee, Brian; Tiersten, Amy
ISI:000208892500105
ISSN: 1527-7755
CID: 1675522

Pathologic response rate in HER2-positive locally advanced breast cancers treated with neoadjuvant trastuzumab and concurrent paclitaxel/radiotherapy [Meeting Abstract]

Adams, Sylvia; Hochman, Tsivia; Huppert, Nelly; Dhage, Shubhada; Checka, Cristina; Singh, Baljit; Speyer, James L; Schneider, Robert; Goldberg, Judith D; Formenti, Silvia
ISI:000318009800278
ISSN: 0732-183x
CID: 1675552

Phase II trial of irinotecan plus bevacizumab for heavily pretreated recurrent ovarian cancer. [Meeting Abstract]

Jain, Salvia Sanjay; Makeyev, Yan G; Muggia, Franco; Speyer, James L; Curtin, John Patrick; Blank, Stephanie V; Boyd, Leslie R; Pothuri, Bhavana; Fishman, David; Li, Xiaochun; Goldberg, Judith D; Tiersten, Amy
ISI:000318009803673
ISSN: 0732-183x
CID: 1675562

Finding ovarian cancer

Hartge, Patricia; Speyer, James L
PMCID:3260133
PMID: 22247023
ISSN: 0027-8874
CID: 155934

Phase II trial of RAD001 plus carboplatin in patients with triple-negative metastatic breast cancer. [Meeting Abstract]

Singh, Jasmeet Chadha; Stein, Stacy; Volm, Matthew; Smith, Julia Anne; Novik, Yelena; Speyer, James L; Meyers, Marlene; Adams, Sylvia; Omene, Coral Oghenerukevwe; Muggia, Franco; Schneider, Robert; Formenti, Silvia; Davis, Samantha; Beardslee, Brian; Tiersten, Amy
ISI:000318009800595
ISSN: 0732-183x
CID: 2142292

Reduction of serum VEGF and IL-6 levels in patients with metastatic breast cancer: Results of a study of PTC299, an oral inhibitor of tumor VEGF synthesis, and aromatase inhibitors [Meeting Abstract]

Dickler, M. N.; Schneider, B. P.; Volm, M.; Speyer, J. L.; Novik, Y.; Callahan, L. A.; Darby, C. H.; Barth, J.; Elfring, G. L.; Ogden, A.; Tiersten, A.
ISI:000208880300238
ISSN: 0732-183x
CID: 3159212

A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies

Seiden, M V; Burris, H A; Matulonis, U; Hall, J B; Armstrong, D K; Speyer, J; Weber, J D A; Muggia, F
OBJECTIVE: The primary objective of this study was to determine the rate of response to matuzumab in patients with recurrent, EGFR-positive ovarian, or primary peritoneal cancer. Secondary end points included safety and tolerability, time to tumor progression, duration of response, and overall survival. METHODS: A multi-institutional single arm phase II trial. RESULTS: Of 75 women screened for the study, 37 were enrolled and treated. Median age of the treated patient population was 58 years, and most patients had more than four prior lines of chemotherapy. Therapy was well tolerated, the most common toxicities being a constellation of skin toxicities, including rash, acne, dry skin, and paronychia, as well as headache, fatigue, and diarrhea. Serious adverse events were very rare but included a single episode of pancreatitis that may have been drug related. All patients completed therapy, receiving 1 to 30 infusions of matuzumab. There were no formal responses (RR=0%, 95% CI: 0-9.5%), although 7 patients (21%) were on therapy for more than 3 months with stable disease. CONCLUSIONS: Matuzumab at the dose and schedule selected is well tolerated. In this population of very heavily pretreated patients with epithelial ovarian and primary peritoneal malignancies, there was no evidence of significant clinical activity when matuzumab was administered as monotherapy.
PMID: 17126894
ISSN: 0090-8258
CID: 161235

Report of first-stage accrual for NCI 5886, a phase II study of erlotinib, carboplatin and paclitaxel as first-line treatment of ovarian cancer [Meeting Abstract]

Blank, SV; Curtin, JP; Goldman, NA; Runowicz, CD; Speyer, JL; Tiersten, AD; Dancey, J; Wadler, S; Muggia, FM
ISI:000239009401529
ISSN: 0732-183x
CID: 69299

Robust control for convection suppression in a fluid layer: The effects of boundary properties, actuator lag, and major parameter uncertainties

Or, A C; Speyer, J L
The robustness of control is a requirement to maintain a fluid layer at conductive equilibrium heated to a highly supercritical condition. Robustness determines how much uncertainties, or design parameter mismatches, can be tolerated. Both linear stability analysis and three-dimensional fully nonlinear simulations are used for the study of the linear quadratic Gaussian (LQG) controller. The parameter mismatches from the nominal conditions are introduced into the plant model, while the LQG compensator assumes nominal conditions. The mismatches arise from boundary properties, actuator lag, sensor level uncertainty, and wall thickness, as well as from the major parameters such as Prandtl number, Rayleigh number, wave number, and truncation number in the reduced-order model. The results suggest that the LQG compensator action can preserve closed-loop stability at over ten times the critical Rayleigh number, provided that the mismatches in the sensor level and wall thickness are small. Mismatches in the Prandtl number and wall material properties have little impact. Mismatches in Rayleigh number and wave number are relatively benign compared with the sensor and thickness parameters. Techniques for measuring the plant output temperature at multiple levels with sufficient accuracy may be an implementation challenge.
PMID: 16711929
ISSN: 1539-3755
CID: 162444